| Sep 16 |
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
|
| Sep 16 |
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
|
| Sep 9 |
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
|
| Sep 3 |
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 26 |
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
|
| Aug 9 |
Zentalis Pharmaceuticals GAAP EPS of -$1.24
|
| Aug 9 |
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
|
| Jun 21 |
(ZNTL) - Analyzing Zentalis Pharma's Short Interest
|
| Jun 20 |
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
|
| Jun 19 |
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
|
